Q-omics provides the consensus-scored ZNF790 profile across patient tissues and cancer cell-line models. ZNF790 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF790 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ZNF790 RNA expression shows 20,987 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where ZNF790 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF790 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF790 survival associations across molecular data types. ZNF790 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF790 RNA expression–survival associations across cancer types. High ZNF790 expression shows unfavorable associations in LGG, CESC, SCLC and READ, but favorable associations in KIRC and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF790 RNA expression.
This table summarizes ZNF790 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF790. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF790 shows lower tumor expression in HNSC, KIRP, THCA and ESCA and higher tumor expression in LUAD and LIHC. The HNSC box plot shows higher ZNF790 RNA expression in normal versus tumor tissue (log2 FC = −0.421, t-test p = .001).
This table shows molecular features associated with ZNF790 in patient tissues and cancer cell lines. In patient samples, ZNF790 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF790 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
